← All C4 Therapeutics, INC filings

C4 Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CCCC
C4 Therapeutics, INC
10-K: C4 Therapeutics Advances Pipeline, Secures Funding
C4 Therapeutics reports 2025 financial results, pipeline progress, and a significant capital raise, extending its operational runway through 2028.
NASDAQ
CCCC
C4 Therapeutics, INC
10-K: C4 Therapeutics Reports 2024 Financial Results, Highlights Clinical Progress
C4 Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and highlights ongoing clinical trials and strategic collaborations.
NASDAQ
CCCC
C4 Therapeutics, INC
10-K: C4 Therapeutics and Merck Forge Collaboration to Develop Novel Cancer Therapies
C4 Therapeutics and Merck have entered into a licensing and collaboration agreement to develop degrader-antibody conjugates for an initial oncology target, with potential for expansion to additional targets.